- Record: found
- Abstract: found
- Article: not found
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson
1 ,
Marzia Capelletti ,
Roman Yelensky ,
Geoff Otto ,
Alex Parker ,
Mirna Jarosz ,
John A Curran ,
Sohail Balasubramanian ,
Troy Bloom ,
Kristina W Brennan ,
Amy Donahue ,
Sean R Downing ,
Garrett M Frampton ,
Lazaro Garcia ,
Frank Juhn ,
Kathy C Mitchell ,
Emily White ,
Jared White ,
Zac Zwirko ,
Tamar Peretz ,
Hovav Nechushtan ,
Lior Soussan-Gutman ,
Jhingook Kim ,
Hidefumi Sasaki ,
Hyeong Ryul Kim ,
Seung-il Park ,
Dalia Ercan ,
Christine E Sheehan ,
Jeffrey S Ross ,
Maureen T Cronin ,
Pasi A Jänne ,
Philip J Stephens
Feb 12 2012
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non-small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma. Further screening of 561 lung adenocarcinomas identified 11 additional tumors with KIF5B-RET gene fusions (2.0%; 95% CI 0.8-3.1%). Cells expressing oncogenic KIF5B-RET are sensitive to multi-kinase inhibitors that inhibit RET.